TELA Bio to Announce Third Quarter 2024 Financial Results
MALVERN, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical technology company…
Pharmaceuticals, Biotechnology and Life Sciences
MALVERN, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical technology company…
The new African American Genetic Groups feature traces customers’ ancestral connections from before the early-to-mid-20th century migrations to more than…
REDWOOD CITY, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) — Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a…
Mean intraocular pressure (IOP) was reduced by 43.7% from baseline at month 18All patients remained off topical IOP-lowering medications and…
Data Show Tesamorelin May Reduce CVD Risk by Reducing EVAFMONTREAL, Oct. 17, 2024 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or…
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF…
NANTES, France, October 17, 6:00pm CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced it will be presenting…
KEY FIGURES Revenue at the end of September €1 042.1M Growth at constant exchange rates and scope1 +8.6%…
BALTIMORE, Oct. 17, 2024 (GLOBE NEWSWIRE) — Rapafusyn Pharmaceuticals, a leader in the field of non-degrading molecular glues, is pleased…
— LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness (EDS) in patients 7 years…